Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group

doi:10.1053/j.gastro.2021.09.011

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry

Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group

Research output: Contribution to journal › Short survey › peer-review

56 Scopus citations

Original language	English
Pages (from-to)	316-319.e5
Journal	Gastroenterology
Volume	162
Issue number	1
DOIs	https://doi.org/10.1053/j.gastro.2021.09.011
State	Published - Jan 2022

Access to Document

10.1053/j.gastro.2021.09.011

Cite this

@article{ebd013a73439459582107077f2a5377d,

title = "Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry",

author = "{Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group} and Ungaro, {Ryan C.} and Brenner, {Erica J.} and Manasi Agrawal and Xian Zhang and Kappelman, {Michael D.} and Colombel, {Jean Frederic} and Gearry, {Richard B.} and Kaplan, {Gilaad G.} and Michele Kissous-Hunt and Lewis, {James D.} and Ng, {Siew C.} and Rahier, {Jean Francois} and Walter Reinisch and Flavio Steinwurz",

note = "Funding Information: The authors would like to acknowledge all health care providers who reported cases to the SECURE-IBD registry. A list acknowledging all reporters can be found at: https://covidibd.org/reporter-acknowledgment/. Richard B. Gearry, Department of Medicine, University of Otago, Christchurch, New Zealand; Gilaad G. Kaplan, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Michele Kissous-Hunt, Fifth Avenue GI, New York, New York; James D. Lewis, The University of Pennsylvania, Philadelphia, Pennsylvania; Siew C. Ng, Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong SAR, The People's Republic of China, Jean-Francois Rahier, Department of Gastroenterology, Universit{\'e} Catholique de Louvain, Yvoir, Belgium, Walter Reinisch, Department Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria; and Flavio Steinwurz, Hospital Israelita Albert Einstein, S{\~a}o Paulo, Brazil. Ryan C. Ungaro, MD MS (Conceptualization: Lead; Formal analysis: Equal; Writing – original draft: Equal). Erica J. Brenner, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Equal). Manasi Agrawal, MD (Data curation: Supporting; Writing – review & editing: Supporting). Richard B. Gearry, MD (Writing – review & editing: Supporting). Gilaad G. Kaplan, MD (Writing – review & editing: Supporting). Michele Kissous-Hunt, MS (Writing – review & editing: Supporting). James D. Lewis, MD (Conceptualization: Supporting; Writing – review & editing: Supporting). Siew C. Ng, MD (Writing – review & editing: Supporting). Jean-Francois Rahier, MD (Writing – review & editing: Supporting). Walter Reinisch, MD (Writing – review & editing: Supporting). Flavio Steinwurz, MD (Writing – review & editing: Supporting). Xian Zhang, PhD (Formal analysis: Lead; Methodology: Supporting; Writing – original draft: Supporting). Michael D. Kappelman, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Supporting). Jean-Frederic Colombel, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Supporting). Conflicts of interest These authors disclose the following: Ryan C. Ungaro: served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; received research support from AbbVie, Boehringer Ingelheim, Eli Lilly, and Pfizer. Richard B. Gearry: speaker fees and Scientific Advisory Boards for AbbVie and Janssen. Gilaad G. Kaplan: Honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, and Takeda; received research support from Ferring, Janssen, Abbvie, GlaxoSmith Kline, Merck, and Shire; ownership of a patent (Treatment of Inflammatory Disorders, Autoimmune Disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. September 7. 2018). Michele Kissous-Hunt: speaker/consultant for AbbVie, Janssen, Takeda. James D. Lewis: personal fees from Johnson & Johnson Consumer Inc, grants, personal fees and other from Takeda Pharmaceuticals, personal fees and nonfinancial support from AbbVie, grants and personal fees from Janssen Pharmaceuticals, personal fees from Eli Lilly and Company, personal fees from Samsung Bioepis, personal fees from UCB, personal fees from Bristol-Myers Squibb, grants and personal fees from Nestle Health Science, personal fees from Bridge Biotherapeutics, personal fees from Celgene, personal fees from Merck, personal fees and other from Pfizer, personal fees from Gilead, personal fees from Arena Pharmaceuticals, personal fees from Protagonist Therapeutics. Siew C. Ng: honoraria for speaking or consultancy from Abbvie, Janssen, Ferring, Tillotts, and Takeda; research support from Ferring and AbbVie. Jean-Francois Rahier: lecture fees from AbbVie, MSD, Takeda, Pfizer, Ferring, and Falk, consulting fees from AbbVie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, and Amgen, and research support from Takeda and AbbVie. Walter Reinisch: speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Gr{\"u}nenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Gr{\"u}nenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC; received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik, and MSD. Jean-Francois Rahier: Consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Celgene, Nestl{\'e} Health Science, Nestl{\'e} Nutrition Institute. Flavio Steinwurz: Speaker and consultant for: AbbVie, Eurofarma, Ferring, Janssen, Pfizer, Sanofi, Takeda, and UCB. Michael D. Kappelman has consulted for AbbVie, Janssen, Pfizer, Eli Lilly, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from AbbVie and Janssen. Jean-Frederic Colombel: received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; received payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development. The remaining authors disclose no conflicts. Funding This work was funded by the Helmsley Charitable Trust (2003-04445), Clinical and Translational Science Awards grant number UL1TR002489, T32DK007634 (Erica J. Brenner), K23KD111995-01A1 (Ryan C. Ungaro), and K23DK129762-01 (Manasi Agrawal). Additional funding provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. Funding Information: Funding This work was funded by the Helmsley Charitable Trust (2003-04445), Clinical and Translational Science Awards grant number UL1TR002489, T32DK007634 (Erica J. Brenner), K23KD111995-01A1 (Ryan C. Ungaro), and K23DK129762-01 (Manasi Agrawal). Additional funding provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. ",

year = "2022",

month = jan,

doi = "10.1053/j.gastro.2021.09.011",

language = "English",

volume = "162",

pages = "316--319.e5",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "1",

}

Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group 2022, 'Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry', Gastroenterology, vol. 162, no. 1, pp. 316-319.e5. https://doi.org/10.1053/j.gastro.2021.09.011

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. / Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group.
In: Gastroenterology, Vol. 162, No. 1, 01.2022, p. 316-319.e5.

Research output: Contribution to journal › Short survey › peer-review

TY - JOUR

T1 - Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease

T2 - Analysis of More Than 6000 Patients From an International Registry

AU - Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group

AU - Ungaro, Ryan C.

AU - Brenner, Erica J.

AU - Agrawal, Manasi

AU - Zhang, Xian

AU - Kappelman, Michael D.

AU - Colombel, Jean Frederic

AU - Gearry, Richard B.

AU - Kaplan, Gilaad G.

AU - Kissous-Hunt, Michele

AU - Lewis, James D.

AU - Ng, Siew C.

AU - Rahier, Jean Francois

AU - Reinisch, Walter

AU - Steinwurz, Flavio

N1 - Funding Information: The authors would like to acknowledge all health care providers who reported cases to the SECURE-IBD registry. A list acknowledging all reporters can be found at: https://covidibd.org/reporter-acknowledgment/. Richard B. Gearry, Department of Medicine, University of Otago, Christchurch, New Zealand; Gilaad G. Kaplan, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Michele Kissous-Hunt, Fifth Avenue GI, New York, New York; James D. Lewis, The University of Pennsylvania, Philadelphia, Pennsylvania; Siew C. Ng, Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong SAR, The People's Republic of China, Jean-Francois Rahier, Department of Gastroenterology, Université Catholique de Louvain, Yvoir, Belgium, Walter Reinisch, Department Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria; and Flavio Steinwurz, Hospital Israelita Albert Einstein, São Paulo, Brazil. Ryan C. Ungaro, MD MS (Conceptualization: Lead; Formal analysis: Equal; Writing – original draft: Equal). Erica J. Brenner, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Equal). Manasi Agrawal, MD (Data curation: Supporting; Writing – review & editing: Supporting). Richard B. Gearry, MD (Writing – review & editing: Supporting). Gilaad G. Kaplan, MD (Writing – review & editing: Supporting). Michele Kissous-Hunt, MS (Writing – review & editing: Supporting). James D. Lewis, MD (Conceptualization: Supporting; Writing – review & editing: Supporting). Siew C. Ng, MD (Writing – review & editing: Supporting). Jean-Francois Rahier, MD (Writing – review & editing: Supporting). Walter Reinisch, MD (Writing – review & editing: Supporting). Flavio Steinwurz, MD (Writing – review & editing: Supporting). Xian Zhang, PhD (Formal analysis: Lead; Methodology: Supporting; Writing – original draft: Supporting). Michael D. Kappelman, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Supporting). Jean-Frederic Colombel, MD (Conceptualization: Equal; Formal analysis: Equal; Writing – original draft: Supporting). Conflicts of interest These authors disclose the following: Ryan C. Ungaro: served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; received research support from AbbVie, Boehringer Ingelheim, Eli Lilly, and Pfizer. Richard B. Gearry: speaker fees and Scientific Advisory Boards for AbbVie and Janssen. Gilaad G. Kaplan: Honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, and Takeda; received research support from Ferring, Janssen, Abbvie, GlaxoSmith Kline, Merck, and Shire; ownership of a patent (Treatment of Inflammatory Disorders, Autoimmune Disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. September 7. 2018). Michele Kissous-Hunt: speaker/consultant for AbbVie, Janssen, Takeda. James D. Lewis: personal fees from Johnson & Johnson Consumer Inc, grants, personal fees and other from Takeda Pharmaceuticals, personal fees and nonfinancial support from AbbVie, grants and personal fees from Janssen Pharmaceuticals, personal fees from Eli Lilly and Company, personal fees from Samsung Bioepis, personal fees from UCB, personal fees from Bristol-Myers Squibb, grants and personal fees from Nestle Health Science, personal fees from Bridge Biotherapeutics, personal fees from Celgene, personal fees from Merck, personal fees and other from Pfizer, personal fees from Gilead, personal fees from Arena Pharmaceuticals, personal fees from Protagonist Therapeutics. Siew C. Ng: honoraria for speaking or consultancy from Abbvie, Janssen, Ferring, Tillotts, and Takeda; research support from Ferring and AbbVie. Jean-Francois Rahier: lecture fees from AbbVie, MSD, Takeda, Pfizer, Ferring, and Falk, consulting fees from AbbVie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, and Amgen, and research support from Takeda and AbbVie. Walter Reinisch: speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC; received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik, and MSD. Jean-Francois Rahier: Consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Celgene, Nestlé Health Science, Nestlé Nutrition Institute. Flavio Steinwurz: Speaker and consultant for: AbbVie, Eurofarma, Ferring, Janssen, Pfizer, Sanofi, Takeda, and UCB. Michael D. Kappelman has consulted for AbbVie, Janssen, Pfizer, Eli Lilly, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from AbbVie and Janssen. Jean-Frederic Colombel: received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; received payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Novartis, PBM Capital, Pfizer, Sanofi, Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development. The remaining authors disclose no conflicts. Funding This work was funded by the Helmsley Charitable Trust (2003-04445), Clinical and Translational Science Awards grant number UL1TR002489, T32DK007634 (Erica J. Brenner), K23KD111995-01A1 (Ryan C. Ungaro), and K23DK129762-01 (Manasi Agrawal). Additional funding provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. Funding Information: Funding This work was funded by the Helmsley Charitable Trust (2003-04445), Clinical and Translational Science Awards grant number UL1TR002489, T32DK007634 (Erica J. Brenner), K23KD111995-01A1 (Ryan C. Ungaro), and K23DK129762-01 (Manasi Agrawal). Additional funding provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85120987330&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.09.011

DO - 10.1053/j.gastro.2021.09.011

M3 - Short survey

C2 - 34529987

AN - SCOPUS:85120987330

SN - 0016-5085

VL - 162

SP - 316-319.e5

JO - Gastroenterology

JF - Gastroenterology

IS - 1

ER -